Compare Dollar Tree, Inc. (DLTR) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Eli Lilly And Co — how do they compare? Dollar Tree, Inc. trades at $118.65 (market cap $21.82B), while Eli Lilly And Co trades at $1,166.02 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 48.6× Dollar Tree, Inc.'s market cap, and Eli Lilly And Co pays a 0.58% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Eli Lilly And Co for 93 Days on average.
| DLTR | LLY | |
|---|---|---|
Market Cap | $21.82B | $1.06T |
Volume | 1,613,659 | 2,297,239 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $1.28K |
52-Week Low | $86.80 | $799.57 |
Typical Hold Time | 58 Days | 93 Days |
Enterprise Value | $28.43B | $1.11T |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $118.62, up 2.09% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 45.87% ROE and trades at a modest P/E of 14.25. Recent news highlights strategic initiatives and store expansions driving growth, though margin risks from tariffs and costs persist. Cash flow trends are positive, with 2025 net cash flow reaching $754 million.
Outlook is positive with a consensus price target of $139.33, implying 17% upside. Key opportunities include continued earnings momentum and store improvements, while risks involve margin pressure from tariffs and reinvestment costs. Analyst sentiment is bullish with 53% buy ratings, but investors should monitor execution on profitability targets.
Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.
Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
